Top Markets
#1 Smilek to the Bank Smilek to the Bank +50.56%
#2 Purr Purr +48.38%
#3 龙虾 (Lobster) 龙虾 (Lobster) +22.75%
#4 DigiByte DigiByte +22.53%
#5 OriginTrail OriginTrail +21.47%
#6 Non-Playable Coin Non-Playable Coin +21.04%
#7 Pons Pons +19.40%
#8 ApeX ApeX +19.29%
#9 Zora Zora +18.63%
#10 Morpho Morpho +17.03%
Coin of the day
Smilek to the Bank Smilek to the Bank
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Hemab Therapeutics Holdings, Inc. Common Stock Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings, Inc. Common Stock

COAG
Rang in Aktien #21709
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm... Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Aktienkurs
$50.82
Zuletzt synchronisiert: 2026-08-11
Marktkapitalisierung
$102.09M
Veränderung (1 Tag)
1.90%
Veränderung (1 Jahr)
-
Land
US
Handel Hemab Therapeutics Holdings, Inc. Common Stock (COAG)

Kategorie

Healthcare
P/B-Verhältnis für Hemab Therapeutics Holdings, Inc. Common Stock (COAG)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Hemab Therapeutics Holdings, Inc. Common Stock beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Hemab Therapeutics Holdings, Inc. Common Stock von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH